On August 25, INNOCARE rose 5.08% in regular trading, trading at HK$14.5/share, with turnover of HK$60.91 million.

The movement was driven by the company's H1 interim results released on August 24. INNOCARE reported revenue of RMB 1.137 billion, up 55.5% year-over-year, and attributable net profit of RMB 246.4 million, returning from a loss of RMB 30.1 million a year ago. Q2 standalone net profit surged 392.43% year-over-year to RMB 141 million. Drug sales revenue reached RMB 918 million, up 43.2%, driven by continued volume growth of BTK inhibitor Orelabrutinib and contributions from newly launched Tafasitamab and Gunagratinib. Gross margin stood at 89.54%, with adjusted profit at approximately RMB 277 million. Cash reserves increased to RMB 8.43 billion as of June 30.

The company noted it has entered a new stage of diversified growth across hematologic oncology, autoimmune diseases, and solid tumors, with multiple products commercialized or nearing regulatory submission, enhancing earnings visibility and expanding its global footprint.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)